Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
78
NCT02797795
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
Phase: Phase 1
Role: Lead Sponsor
Start: Dec 31, 2016
Completion: Dec 31, 2021